Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

@article{Wells2008AlendronateFT,
  title={Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.},
  author={George A Wells and Ann Cranney and Jeffrey H Peterson and Matthieu Boucher and Beverley Shea and Vivian Robinson and Doug Coyle and Peter Tugwell},
  journal={The Cochrane database of systematic reviews},
  year={2008},
  volume={1},
  pages={CD001155}
}
BACKGROUND Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which act to inhibit bone resorption by interfering with the activity of osteoclasts. OBJECTIVES To assess the efficacy of alendronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women. SEARCH STRATEGY We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled… CONTINUE READING